Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 4, 2026Kidney Research and Clinical PracticeOpen Access

SGLT2i, GLP-1RA, and finerenone provide integrated cardio-kidney-metabolic benefits beyond glycemic control in T2D.

View Full Paper
Ask AI
Bookmark
Share

Design

Review

Key result

Novel therapies such as SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone provide integrated cardio-kidney-metabolic benefits beyond glycemic control in patients with type 2 diabetes.

Authors

YKYaeni KimELEun Young LeeOGOn behalf of the Korean Diabetic Kidney Disease Study Group

Discussion

Loading...

Member takes

Overview

May support integrated cardio-kidney-metabolic therapy in T2D; leaves open optimal sequencing and combinations.

Key Points

  • To review the mechanisms and clinical evidence of incretin-based therapies in addressing residual renal and cardiovascular risk in diabetic kidney disease within the cardio-kidney-metabolic framework.
  • Synthesized translational and clinical trial evidence evaluating selective GLP-1 receptor agonists, dual GIP/GLP-1 agonists, and triple GIP/GLP-1/glucagon agonists.
  • Analyzed renal and cardiovascular outcomes across major clinical trials, including the FLOW trial in patients with type 2 diabetes and chronic kidney disease.
  • GLP-1 receptor agonists demonstrated a 24% reduction in major kidney outcomes in patients with type 2 diabetes and chronic kidney disease in the FLOW trial.
  • Incretin activation improves intrarenal hemodynamics, alleviates metabolic decongestion, and attenuates inflammatory and fibrotic signaling cascades.
  • Dual and triple incretin receptor agonists, such as tirzepatide and retatrutide, provide superior weight loss and metabolic reprogramming with emerging cardio-renal benefits.

PICO

P
Population
Cardio-metabolic-renal disease
I
Intervention / Comparator
Novel glucose-lowering therapies (SGLT2i, GLP-1 RA, Finerenone, Tirzepatide)

The paper provides a comprehensive overview of the cardio-metabolic-renal connection, emphasizing how dysfunction in one system exacerbates pathology in the others.

Limitations

  • Lack of head-to-head drug comparative trials
  • Need for outcomes trials testing combination therapies
  • Need for clinical trials in specific populations such as women, young individuals, and primary prevention

Cite This Study

Kim et al. (2026) conducted a review in Cardio-metabolic-renal disease. Novel glucose-lowering therapies (SGLT2i, GLP-1 RA, Finerenone, Tirzepatide) was evaluated. Novel therapies such as SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone provide integrated cardio-kidney-metabolic benefits beyond glycemic control in patients with type 2 diabetes.

synapsesocial.com/papers/6a9a85b05d9e33f25c630ff5https://doi.org/10.23876/j.krcp.26.272
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs2025 · 8 citations
  2. 2Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond2025 · 10 citations
  3. 3SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome2025 · 32 citations
  4. 4Rapidly changing landscape of diabetic kidney disease management: recent advances and the road ahead2026
  5. 5Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes2026 · 8 citations